Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Aptevo Therapeutics Inc. (NASDAQ: APVO).

Full DD Report for APVO

You must become a subscriber to view this report.


Recent News from (NASDAQ: APVO)

Aptevo Therapeutics Pushes Higher On The Back Of IXINITY Performance
Aptevo Therapeutics' ( APVO ) Q'18 results were mostly inline. First quarter EPS came in at -$0.63 missing by $0.07, and revenue came in a notch higher by $0.07M. The real positive twist was the company's IXINITY product, which is finally gaining traction. For the quarter IXINITY reven...
Source: SeekingAlpha
Date: May, 15 2018 12:35
Wired News - Arrowhead Pharma Presented Preclinical Data on Expanding Pipeline of RNAi Therapeutics for Cardiometabolic Diseases
Stock Monitor: Aptevo Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 15, 2018 / If you want access to our free research report on Arrowhead Pharma, Inc. (NASDAQ: ARWR ), all you need to do is sign up now by clicking the following link www.active-investors.com/regi...
Source: ACCESSWIRE IA
Date: May, 15 2018 07:40
Aptevo Therapeutics misses by $0.07, beats on revenue
Aptevo Therapeutics (NASDAQ: APVO ): Q1 EPS of -$0.63 misses by $0.07 . More news on: Aptevo Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 10 2018 09:05
Aptevo Therapeutics Reports First Quarter 2018 Financial Results
Almost Doubles Year-Over-Year IXINITY Quarterly Revenue Files IND for APVO436 and Advances APVO210 Toward a Planned Q4 2018 IND Submission Presents Data at AACR Annual Meeting Showing Best-in-Class Potential for APVO436 Versus a Competitor Molecule SEATTLE, May 10, 2018 (GLOBE...
Source: GlobeNewswire
Date: May, 10 2018 09:00
New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 Presented by Aptevo Therapeutics and Alligator Bioscience at Prominent Industry Conferences
ALG.APV-527 is Designed to Strategically Target and Engage the Immune System for the Potential Treatment of Multiple Solid Tumor Indications SEATTLE and LUND, Sweden, May 08, 2018 (GLOBE NEWSWIRE) --  Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on dev...
Source: GlobeNewswire
Date: May, 08 2018 09:02
3 Things In Biotech, May 3: Bristol Bows Out Of IDO, And Two Biotechs Look To Investigate Novel Immunotherapies
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated...
Source: SeekingAlpha
Date: May, 04 2018 08:00
Aptevo Therapeutics Announces IND Submission for APVO436
New Preclinical Data Presented at AACR Support Best-in-Class Features of APVO436 Highlighting Reduced Cytokine Release and Antibody-Like Half-Life and Manufacturing On Track to Commence Phase 1 Clinical Trial of APVO436 in Acute Myeloid  Leukemia and Myelodysplastic Syndrome in ...
Source: GlobeNewswire
Date: May, 01 2018 09:00
Report: Developing Opportunities within Natus Medical, Aptevo Therapeutics, Revlon, Silgan, Resources Connection, and TrustCo Bank Corp NY - Future Expectations, Projections Moving into 2018
NEW YORK, April 30, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Natus Medical Incorporated (NASDAQ:BABY), Aptevo Therapeutics Inc. (NASD...
Source: GlobeNewswire
Date: April, 30 2018 07:50
Aptevo Therapeutics' Bispecific Antibody APVO436 Shows Robust T-Cell Activation With Minimal Cytokine Release
New Preclinical Data Presented at the 2018 American Association for Cancer Research  Annual Meeting Show Potent T-Cell Directed Tumor Killing with Reduced Cytokine Production Compared to a Competitor Bispecific Construct SEATTLE, April 16, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeut...
Source: GlobeNewswire
Date: April, 16 2018 09:02
Premarket Gainers as of 9:05 am (04/11/2018)
VHC +23%  on Apple (NASDAQ: AAPL ) patent victory . More news on: VirnetX Holding Corporation, Apple Inc., SemiLEDs Corporation, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: April, 11 2018 09:21

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-215.355.255.375.1641,914
2018-08-205.805.325.805.211112,767
2018-08-175.665.365.685.3163,545
2018-08-165.495.605.775.29184,407
2018-08-155.295.445.725.20226,903

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-213,81711,00634.6811Cover
2018-08-2015,24726,00358.6355Short
2018-08-1712,84622,39457.3636Short
2018-08-1623,63246,29851.0432Short
2018-08-1540,45172,34555.9140Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on APVO.


About Aptevo Therapeutics Inc. (NASDAQ: APVO)

Logo for Aptevo Therapeutics Inc. (NASDAQ: APVO)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: APVO)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 10 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 20 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 20 2018
      Amendment to a previously filed Form 4
      Filing Type: 4/AFiling Source: edgar
      Filing Date: March, 21 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 13 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 13 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: January, 08 2018

       

       


      Daily Technical Chart for (NASDAQ: APVO)

      Daily Technical Chart for (NASDAQ: APVO)


      Stay tuned for daily updates and more on (NASDAQ: APVO)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: APVO)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in APVO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of APVO and does not buy, sell, or trade any shares of APVO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/